The NEAT Study is about obesity, appetite, emotions, and how the brain develops in children. The study team is looking for volunteer youth to participate who are either healthy or have a clinical condition called Congenital Adrenal Hyperplasia (CAH).
This is a Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of crinecerfont versus placebo administered twice daily (bid) with breakfast and evening meals for28 weeks in approximately 81 pediatric subjects with classic congenital adrenal hyperplasia (CAH) due to21-hydroxylase deficiency. Eligible subjects will be randomly assigned in a 2:1 ratio (active:placebo) to either crinecerfont (25 mg bid via oral solution for subjects 10 to <20 kg, 50 mg bid via oral solution for subjects 20 to <55 kg, or 100 mg bid via oral capsules for subjects ≥55 kg) or matching placebo (oral solution placebo for subjects <55 kg and oral capsule placebo for subjects ≥55 kg). Dose assignment from Day 1 to Week 28 will be based on the subject’s weight at Day 1. After the 28-week placebo-controlled treatment period, there will be a 24-week, open-label treatment period, during which all subjects will receive crinecerfont at doses based on their Week 28 body weight.
1. To identify family members of people with type 1 diabetes that may be at risk for developing type 1 diabetes. 2. To monitor the metabolic and immunologic status of at-risk individuals. Eligible individuals will be offered enrollment in type 1 diabetes prevention studies. See website for more details https://www.trialnet.org/
This is an observational study that employs qualitative methods (13 focus groups and 22 individual interviews) targeting 130 sexually active and non-sexually active adolescent and young adult (AYA) females, living with chronic illness or disability. The study is designed to explore the extent to which their experiences living with chronic illness and engagement in ongoing medical management has an impact on their contraception decision making and perception of LARC as a viable option.
The aim is to find out how overall health and wellness is related to need for pain medication after surgery.
This research is being done to test the safety and effectiveness of intranasal carbetocin to treat Prader Willi Syndrome.
To demonstrate that an ultra-fast-acting formulation of insulin lispro is non-inferior to Humalog on measures of glycemic control when administered 0 to 2 minutes before eating in combination with basal insulin.
This is a Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of NBI-74788 versus placebo administered bid with breakfast and the evening meal (doses separated by approximately 12 hours) for 24 weeks in approximately 165 adult subjects with classic CAH due to 21-hydroxylase deficiency.
This is a randomized trial to help determine which of two gold standard treatments, Medication or Cognitive Behavioral Therapy (CBT), or their combination, is most effective when treating anxiety disorders in children and adolescents. Treatment of every child with an anxiety disorder begins with the question of which treatment to start first, and then what to do if that initial treatment is not as helpful as it should be. This study will help patients, families, and clinicians determine which treatment sequences are most helpful for which specific patients.
